Lyme disease prevention: Tarsus Pharmaceuticals initiates clinical trial for oral, non-vaccine TP-05

By NewsDesk @infectiousdiseasenews TP-05 is designed to kill infected ticks attached to the human body before they can transmit the Borrelia bacteria that causes Lyme disease Late clinical-stage biopharmaceutical company, Tarsus Pharmaceuticals, announced that it has initiated dosing participants in its first clinical trial for TP-05, a novel, oral, non-vaccine therapeutic for the prevention of Lyme [...]

The post Lyme disease prevention: Tarsus Pharmaceuticals initiates clinical trial for oral, non-vaccine TP-05 appeared first on Outbreak News Today.